Association between oral fluoroquinolone use and retinal detachment

JAMA Ophthalmology

Volumn 134, Issue 4, 2016, Pages 415-421

  Raguideau, Fanny ^a   Lemaitre, Magali ^a   Dray Spira, Rosemary ^a   Zureik, Mahmoud ^a  

^a Department of Epidemiology of Health Products   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; HUMAN TISSUE; ICD-10; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD; MIDDLE AGED; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RETINA DETACHMENT; RISK FACTOR; TREATMENT DURATION; AGE DISTRIBUTION; AGED; CASE CONTROL STUDY; CHEMICALLY INDUCED; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DOSE RESPONSE; FACTUAL DATABASE; FRANCE; INCIDENCE; ODDS RATIO; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REFERENCE VALUE; RETINAL DETACHMENT; RISK ASSESSMENT; SEX RATIO; STATISTICAL MODEL;

ADMINISTRATION, ORAL; ADULT; AGE DISTRIBUTION; AGED; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROQUINOLONES; FRANCE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; RETINAL DETACHMENT; RISK ASSESSMENT; SEX DISTRIBUTION;

EID: 84963613111     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2015.6205     Document Type: Article

References (35)

1. Kang HK, Luff AJ. Management of retinal detachment: a guide for non-ophthalmologists. BMJ. 2008;336(7655):1235-1240.
2. Etminan M, Forooghian F, Brophy JM, Bird ST, Maberley D. Oral fluoroquinolones and the risk of retinal detachment. JAMA. 2012;307(13): 1414-1419.
3. Kuo SC, Chen YT, Lee YT, et al. Association between recent use of fluoroquinolones and rhegmatogenous retinal detachment: a population-based cohort study. Clin Infect Dis. 2014;58(2):197-203.
4. Pasternak B, Svanström H, Melbye M, Hviid A. Association between oral fluoroquinolone use and retinal detachment. JAMA. 2013;310(20): 2184-2190.
5. Kapoor KG, Hodge DO, St Sauver JL, Barkmeier AJ. Oral fluoroquinolones and the incidence of rhegmatogenous retinal detachment and symptomatic retinal breaks: a population-based study. Ophthalmology. 2014;121 (6):1269-1273.
6. Fife D, Zhu V, Voss E, Levy-Clarke G, Ryan P. Exposure to oral fluoroquinolones and the risk of retinal detachment: retrospective analyses of two large healthcare databases. Drug Saf. 2014;37(3): 171-182.
7. Eftekhari K, Ghodasra DH, Haynes K, Chen J, Kempen JH, VanderBeek BL. Risk of retinal tear or detachment with oral fluoroquinolone use: a cohort study. Pharmacoepidemiol Drug Saf. 2014;23(7): 745-752.
8. Chui CS, Wong IC, Wong LY, Chan EW. Association between oral fluoroquinolone use and the development of retinal detachment: a systematic review and meta-analysis of observational studies. J Antimicrob Chemother. 2015;70(4):971-978.
9. Chui CS, Man KK, Cheng CL, et al. An investigation of the potential association between retinal detachment and oral fluoroquinolones: a self-controlled case series study. J Antimicrob Chemother. 2014;69(9):2563-2567.
10. Rampal S, Kaur R, Sethi R, Singh O, Sood N. Ofloxacin-associated retinopathy in rabbits: role of oxidative stress. Hum Exp Toxicol. 2008;27(5): 409-415.
11. Ford MM, Dubielzig RR, Giuliano EA, Moore CP, Narfström KL. Ocular and systemic manifestations after oral administration of a high dose of enrofloxacin in cats. Am J Vet Res. 2007;68(2): 190-202.
12. Ramirez CJ, Minch JD, Gay JM, et al. Molecular genetic basis for fluoroquinolone-induced retinal degeneration in cats. Pharmacogenet Genomics. 2011;21(2):66-75.
13. Samarakoon N, Harrisberg B, Ell J. Ciprofloxacin-induced toxic optic neuropathy. Clin Experiment Ophthalmol. 2007;35(1):102-104.
14. Sirbat D, Saudax E, Hurault de Ligny B, Hachet E, Raspiller A. Serous macular detachment of the neuro-epithelium and flumequine [in French]. J Fr Ophtalmol. 1983;6(10):829-836.
15. Ponsioen TL, van Luyn MJ, van der Worp RJ, van Meurs JC, Hooymans JM, Los LI. Collagen distribution in the human vitreoretinal interface. Invest Ophthalmol Vis Sci. 2008;49(9): 4089-4095.
16. Ponsioen TL, Hooymans JM, Los LI. Remodelling of the human vitreous and vitreoretinal interface: a dynamic process. Prog Retin Eye Res. 2010;29(6):580-595.
17. Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 2003;36(11):1404-1410.
18. Hall MM, Finnoff JT, Smith J. Musculoskeletal complications of fluoroquinolones: guidelines and precautions for usage in the athletic population. PM R. 2011;3(2):132-142.
19. van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH. Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med. 2003;163(15):1801-1807.
20. Wise BL, Peloquin C, Choi H, Lane NE, Zhang Y. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med. 2012;125(12):1228.e23-1228.e28.
21. Consiglio GP, Burden AM, Maclure M, McCarthy L, Cadarette SM. Case-crossover study design in pharmacoepidemiology: systematic review and recommendations. Pharmacoepidemiol Drug Saf. 2013;22(11):1146-1153.
22. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2): 144-153.
23. Maclure M, Fireman B, Nelson JC, et al. When should case-only designs be used for safety monitoring of medical products? Pharmacoepi-demiol Drug Saf. 2012;21(suppl 1):50-61.
24. Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc JL, Sailler L. French health insurance databases: what interest for medical research? Rev Med Interne. 2015;36(6):411-417.
25. Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique. 2010;58(4):286-290.
26. Martin-Latry K, Bégaud B. Pharmacoepidemio-logical research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf. 2010;19(3):256-265.
27. Bouillon K, Bertrand M, Maura G, Blotière PO, Ricordeau P, Zureik M. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Lancet Haematol. 2015;2(4): e150-e159.
28. Raguideau F, Mezzarobba M, Zureik M, Weill A, Ricordeau P, Alla F. Compliance with pregnancy prevention plan recommendations in 8672 French women of childbearing potential exposed to acitretin. Pharmacoepidemiol Drug Saf. 2015;24(5): 526-533.
29. Colas S, Collin C, Piriou P, Zureik M. Association between total hip replacement characteristics and 3-year prosthetic survivorship: a population-based study. JAMA Surg. 2015;150(10): 979-988.
30. Tricotel A, Collin C, Zureik M. Impact of the sharp changes in the use of contraception in 2013 on the risk of pulmonary embolism in France. J Thromb Haemost. 2015;13(9):1576-1580.
31. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006; 25(10):1768-1797.
32. Hurault de Ligny B, Sirbat D, Kessler M, Trechot P, Chanliau J. Ocular side effects of flumequine: 3 cases of macular involvement [in French]. Therapie. 1984;39(5):595-600.
33. van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ. 2002;324 (7349):1306-1307.
34. Szarfman A, Chen M, Blum MD. More on fluoroquinolone antibiotics and tendon rupture [comment]. N Engl J Med. 1995;332(3):193.
35. Nordmann S, Biard L, Ravaud P, Esposito-Farèse M, Tubach F. Case-only designs in pharmacoepidemiology: a systematic review. PLoS One. 2012;7(11):e49444.